Company news

Sutro Biopharma, Inc. news in 2020

Sutro Biopharma, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares

December 10, 2020

Sutro Biopharma Announces Pricing of $126.0 Million Public Offering

December 7, 2020

Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock

December 6, 2020

Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer

December 2, 2020

Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors

November 30, 2020

Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer

November 23, 2020

Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations

November 17, 2020

Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments

November 4, 2020

Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting

September 1, 2020

Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

August 24, 2020

Sutro Biopharma Announces Two Executive Promotions to Vice President of Quality and Vice President of Manufacturing

August 10, 2020

Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments

August 5, 2020

Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller

May 20, 2020

Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

May 13, 2020

Sutro Biopharma Announces Proposed Public Offering

May 10, 2020

Sutro Biopharma Announces Pricing of $85.3 Million Public Offering

May 10, 2020

Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer

April 26, 2020

Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate

April 19, 2020

Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments

March 15, 2020

Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck

March 11, 2020

Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development

February 4, 2020

Sutro Biopharma Appoints James Panek to Board of Directors

January 7, 2020

Decks in 2020